Unity Biotechnology (NASDAQ:UBX) Given New $4.00 Price Target at Chardan Capital

Unity Biotechnology (NASDAQ:UBXFree Report) had its price objective trimmed by Chardan Capital from $6.00 to $4.00 in a report issued on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright lowered their price target on shares of Unity Biotechnology from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Monday.

View Our Latest Report on Unity Biotechnology

Unity Biotechnology Stock Down 2.7 %

UBX stock opened at $1.27 on Tuesday. The business’s 50-day moving average price is $1.90 and its 200-day moving average price is $1.51. The stock has a market cap of $21.34 million, a P/E ratio of -0.97 and a beta of 1.02. Unity Biotechnology has a twelve month low of $0.94 and a twelve month high of $3.10.

Hedge Funds Weigh In On Unity Biotechnology

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC increased its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBXFree Report) by 9.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the quarter. Geode Capital Management LLC owned about 0.97% of Unity Biotechnology worth $240,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 29.49% of the company’s stock.

About Unity Biotechnology

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

Read More

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.